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Abstract
Background: Global chronic urticaria (CU) disease experience and management is not well documented. This study
descriptively compares these aspects among CU patients residing in Europe (EU) and Central and South America (C/SA).
Methods: AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global prospective,
non-interventional study of CU in the real-world setting. Patients were ≥ 18 years with a diagnosis of H1-
antihistamine-refractory CU for > 2 months. Differences between the EU and C/SA regions in demographic
and clinical characteristics, quality of life (QoL), work and activity impairment, pharmacological treatment,
and healthcare resource use were examined.
Results: In total, 4224 patients were included in the analysis (C/SA 492; EU 3732). Rates of untreated patients were
greater in the C/SA region (45.1% vs. 31.9%; P < 0.005) and escalation to third-line therapy was rare in both regions.
Differences in disease experience emerged, with C/SA patients more commonly experiencing angioedema (C/SA 50.
8% vs. EU 46.1%; P = 0.03) or comorbid chronic inducible urticaria (C/SA 30% vs. EU 22%; P < 0.001). Correspondingly,
rates of uncontrolled urticaria were higher among C/SA patients (82.8% vs. 77.5%; P = 0.017) and patients in the C/SA
region showed significantly greater work and activity impairment (absenteeism: 10.4 ± 19.7 vs. 6.7 ± 19.0, P = 0.004;
presenteeism: 30.3 ± 31.9 vs. 24.4 ± 25.8, P = 0.001; work productivity loss: 33.9 ± 33.9 vs. 26.5 ± 27.5, P < 0.001; activity
impairment: 37.7 ± 34.7 vs. 32.7 ± 30.1, P = 0.001). However, QoL impairment was greater in the EU region (Dermatology
Life Quality Index: C/SA 6.5 ± 5.9 vs. EU 8.3 ± 7.0; P < 0.001). There was a significant difference in use of healthcare
resources, including emergency services (39.6% vs. 29.3%; P < 0.001), hospitalization (7.7% vs 21.9%; P < 0.001) general
practitioners (31.7% vs 57.3%; P < 0.001), and additional allergists or dermatologists (50.6% vs. 47.3%, P < 0.001), among
patients in the C/SA and EU region, respectively. In both regions, patients with a primary diagnosis of CU
with angioedema had significantly greater impairment in work and non-work activities and healthcare resource utilization
compared to those without angioedema.
Conclusions: This study revealed that CU is a heterogeneous condition with differences in healthcare utilization and
outcomes between EU and C/SA. However, overall there is a high unmet need of H1-antihistamine-refractory
CU patients, which is associated with high use of healthcare resources, and has a large negative effect on QoL
and work productivity.
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Background
Chronic urticaria (CU) is a skin disorder in which red,
swollen, itchy, and sometimes painful hives (wheals), an-
gioedema, or both, repeatedly occur for more than
6 weeks [1]. Hives may occur with or without angio-
edema (swelling in the deep layers of the skin that
causes itch, pain or burning), particularly around the
eyes, lips, cheeks, hands, feet, and genitals [2]. Likewise,
recurrent angioedema may occur with or without
wheals. The estimated prevalence of CU is up to 1% in
the general population [3], with those aged between 30
and 50 years most commonly affected, and females af-
fected approximately twice as often as males [4–7]. A
further distinction is made between urticarias with spon-
taneously occurring signs and symptoms – chronic
spontaneous urticaria (CSU) – and those where wheals
and angioedema are induced by specific stimuli (in-
cluding cold, heat, solar, delayed pressure, vibratory,
dermographic, aquagenic, cholinergic, contact, and ex-
ercise – chronic inducible urticaria (CIndU) [8–11].
Patients may concurrently experience CSU and CIndU
in approximately 20% of cases [5].
While the condition is not life threatening, the impact
of the disorder on patient quality of life, work productivity,
and activities of daily living have been well documented
[12–14]. To improve symptom control and minimize dis-
ease burden among CU patients, international guidelines
have been developed, which recommend a stepwise
treatment approach [1]. Initial treatment should consist of
labelled doses of second-generation non-sedating H1-
antihistamines (sgH1-AH). Where an inadequate response
is observed after 2–4 weeks or earlier if symptoms are in-
tolerable, up-titration (up to four times) of the H1-AH
dose is recommended. If inadequate symptom relief per-
sists after 4 weeks of the higher dose H1-AH, the previous
version of the EAACI/GA2LEN/EDF/WAO guidelines
(relevant at the time of the AWARE study) recommended
add-on treatment with montelukast, omalizumab, or
ciclosporin [15, 16]. The 2017 version of the guideline
recommends omalizumab as third line treatment and
ciclosporin A as fourth line treatment [1], although no
recommendations are made regarding the length of time
that such treatment should be administered. Available lit-
erature suggests that the guideline recommendations have
not been consistently followed, leading to an unmet need
within the CU population [12, 17–21].
The majority of published data on H1-refractory CU is
limited to patient populations derived from specialized ur-
ticaria centers and thus is not representative of the general
population of patients with CU. To collect data from a
representative sample of CU patients across the world, the
AWARE (a World-wide Antihistamine-Refractory chronic
urticaria patient Evaluation) non-interventional, prospect-
ive observational study was designed. The AWARE study
assesses therapy regimens, burden of disease, and health-
care resource utilization among H1-antihistamine refrac-
tory adult CU patients treated by either office-based
dermatologists and allergists or specialized urticaria
centres. Baseline results of the AWARE study have been
reported for Germany [13] and Scandinavia [22]. The
prevalence and demographic composition is thought to be
similar across the world, but the differences and similar-
ities in disease experience and the effects of the disease
are not well documented. Here, we use the baseline results
of the AWARE study to assess the differences and similar-
ities in the experience of urticaria by comparing two pa-
tient populations that differ culturally, specifically in terms
of health care systems. Thus, we compare data among the
included countries across the European Union (EU) re-
gion and those across the Central and South America (C/
SA) region. Reported data include population characteris-
tics, disease activity, disease subtype, angioedema rates,
pharmacological treatment, disease-specific quality of life
(QoL), work productivity and activity impairment, and
rates of healthcare resource utilization.
Methods
Patients and study design
AWARE was a prospective observational non-interventional
study that followed CU patients for 2 years, refractory to the
approved dose of at least one H1-antihistamine. The
present study reports on patients who were enrolled
in urticaria centres and office-based dermatological
and allergological practices between March 2014 and
April 2016. Clinics that indicated interest in partici-
pating were visited prior to study commencement.
To be included within the study, patients had to meet
the following criteria: a medically confirmed diagnosis of
CU that had been present for at least 2 months; refrac-
tory to treatment with H1-antihistamine; at least 18 years
of age; able and willing to provide informed consent.
Patients were excluded from the study if they were par-
ticipating in a clinical trial, or if difficulties were antici-
pated with patient follow-up.
A total of 4232 H1-antihistamine refractory CSU pa-
tients were enrolled from 458 sites worldwide, including
Belgium, Germany, Denmark, Spain, France, the United
Kingdom, Greece, Italy, Norway, Portugal, Russia,
Sweden, Argentina, Brazil, Colombia, Costa Rica, the
Dominican Republic, Guatemala, Honduras, Panamá,
and Perú. A total of 4224 patients met the inclusion cri-
teria (n = 8 were excluded: n = 4 patients were missing
data on age and n = 4 were aged < 18 years and thus did
not meet inclusion criteria), comprised of 3732 patients
from the EU and 492 patients from the C/SA region.
Table 1 shows the number of eligible patients recruited
within each country.
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Outcome measures
During the first visit, the following information was col-
lected and analysed: demographics (age, gender, height,
and weight); clinician-reported diagnosis (CSU and
CIndU, with or without angioedema); disease control,
measured by the Urticaria Control Test (UCT [23]);
patient-reported quality of life, measured by the Derma-
tology Life Quality Index (DLQI [24]); patient-reported
work and activity impairment, measured by the Work,
Productivity, and Activity Impairment questionnaire
(WPAI [25]); clinician-reported current and prior
(within the past 12 months, but not currently received)
pharmacological treatment for CU; patient-reported sat-
isfaction with treatment, measured on a Visual Analogue
Scale (VAS) ranging from 0 (totally unsatisfied) to 10
(completely satisfied); and, clinician-reported frequency
of healthcare resource use due to urticaria (from the
time of first report of CU symptoms).
The UCT is a disease-specific measure consisting of
four questions that retrospectively assesses patients’
burden of disease over the previous 4 weeks.
Concepts covered include disease activity, QoL, dis-
ease control, and therapy. A total score from 0 to 16
points is derived, with a score of ≥12 indicating dis-
ease control [23, 26].
The DLQI is a dermatologic-specific QoL instrument
consisting of 10 items covering six domains: symptoms
and feelings, daily activities, leisure, work and school,
personal relationships, and treatment [27]. A total score
from 0 to 30 points is derived, and can be banded in the
following ways: 0–1 no effect of CU on QoL; 2– moder-
ate effect of CU on QoL; 6–10 large effect of CU on
QoL; 11–20 very large effect of CU on QoL; and, 21–30
extremely large effect of CU on QoL [28].
The WPAI was used to evaluate work productivity and
activity impairment due to chronic urticaria with the aid
of six short questions relating to absenteeism (the per-
centage of work time missed due to urticaria), presentee-
ism (the percentage of impairment experienced while at
work), overall work productivity (an overall work impair-
ment estimate based on absenteeism and presenteeism)
and overall activity impairment (the percentage of im-
pairment in daily activities) over the previous 7 days.
Only employed patients were asked to respond to the
work-related questions, whereas all patients respond to
the activity-related questions.
Statistical analysis
Data derived from countries within the EU region were
pooled and compared against pooled data from coun-
tries within the C/SA region. Means, medians, standard
deviation (SD), minimum and maximum are stated for
quantitative measurements and absolute and relative fre-
quencies for categorical measurements. Tests for statisti-
cally significant differences at the 5% level (i.e., P < 0.05)
were applied, with one-way analysis of variance
(ANOVA) used to compare differences in means, and
chi2 tests of distribution used to compare differences in
sample distribution for categorical variables. The Bonferroni
correction was applied to all conducted ANOVA tests,
to reduce the chances of type I error which may arise
when multiple pair-wise tests are performed.
Due to the observational nature of the study, incom-
plete data was present for some variables. No statistical
missing data management strategies (e.g. imputation)
were applied. Where missing data were present for cat-
egorical response variables the proportion of patients
with missing data was included, unless otherwise noted.
All analyses were conducted using the statistical soft-
ware packages Stata (version 14) or SAS (version 9.2).
Results
CSU patients in central and South America are more likely
to be young and female than CSU patients in Europe
Patients in the C/SA region were significantly younger
(42.0 ± 13.8 vs. 46.0 ± 15.5; P < 0.001) and more likely to
be female (79.3% vs. 70.8%; P < 0.001) compared with pa-
tients in the EU region (Table 2).
Table 1 Patient distribution within each country
Number of recruited,
eligible patients
Region EU Belgium 80
Germany 2254
Denmark 82
Spain 277
France 92
United Kingdom 264
Greece 145
Italy 249
Norway 50
Portugal 76
Russia 135
Sweden 28
Region C/SA Argentina 96
Brazil 100
Colombia 77
Costa Rica 24
Dominican Republic 54
Guatemala 30
Honduras 51
Panama 25
Peru 35
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CSU patients in central and South America are more likely
to also have CIndU
Among patients with CSU, CIndU was a comorbid dis-
ease in 30% of C/SA patients but only 22% of EU pa-
tients (P < 0.001). CSU patients in the C/SA region were
significantly more likely to have comorbid symptomatic
dermographism than those in the EU region (P = 0.04,
Fig. 1). CSU patients in the EU region were significantly
more likely to have cholinergic (P = 0.001) or cold urti-
caria (P = 0.02).
CSU patients in central and South America have shorter
time since diagnosis than patients in Europe
Within the C/SA region, the mean time since diagnosis
in patients with CSU-only and patients with comorbid
CSU and CIndU was 2.8 ± 4.8 and 3.7 ± 5.0 years, re-
spectively, which was significantly shorter than in the
EU region (4.6 ± 7.1 and 5.4 ± 7.0 years, P = 0.02 and
0.03, respectively).
Angioedema occurs more often in CSU patients in central
and South America
A significantly greater proportion of C/SA vs. EU patients
had angioedema (50.8% vs. 46.1%; P = 0.03). Angioedema
had occurred during the previous 6 months in 47.4% of C/
SA patients vs. 42.6% of EU patients (P = 0.03). However,
angioedema was rated more severely by patients in the
EU: severe, moderate, mild, and negligible angioedema, re-
spectively, were reported by 22.9%, 43.1%, 30.1%, and
2.7%, of EU patients vs. 12.9%, 45.9%, 40.8%, and 0% of pa-
tients in the C/SA region (P < 0.001).
CSU patients in central and South America show lower
rates of controlled disease than patients in Europe
Patients in the C/SA region had significantly lower UCT
scores than those in Europe (7.2 ± 4.1 vs. 7.7 ± 4.3; P =
0.02), with a significantly greater proportion of patients
in the C/SA region experiencing uncontrolled urticaria
(UCT score < 12) compared to EU patients (82.8% vs.
77.5%; P = 0.01).
CU patients in central and South America show higher
rates of no treatment than patients in Europe
Rates of untreated patients (i.e., patients refractory to
the approved dose of at least one H1-antihistamine, who
were not currently receiving treatment) were high in
both regions, but C/SA patients were significantly more
likely to go untreated (45.1% vs. 31.9%; P < 0.005).
Table 2 Baseline demographic and clinical characteristics of H1- antihistamine-refractory CU patients
Region EU Region C/SA Significance Test Statistic
Age (years) 46.0 ± 15.5 42.0 ± 13.8 F = 29.57; P < 0.001
Female: n (%) 2642 (70.8) 390 (72.3) Chi2 = 15.350; P < 0.001
BMI (kg/m2)a 26.8 ± 5.4 26.3 ± 4.2 F = 1.58; P = 0.209
Underweight: n (%) 43 (1.3) 4 (1.7) Chi2 = 5.436; P = 0.143
Healthy weight: n (%) 1361 (40.9) 99 (40.7)
Overweight: n (%) 1157 (34.8) 98 (40.3)
Obese: n (%) 764 (23.0) 42 (17.3)
Diagnosis: n (%)
CSU only 2725 (73.1) 303 (65.3) Chi2 = 17.285; P = 0.001
CIndU only 215 (5.8) 31 (6.7)
Both CSU and CIndU 756 (20.3) 129 (27.8)
CSU with angioedema 1721 (46.1) 250 (50.8) Chi2 = 6.839; P = 0.03
Time since diagnosis (years) 4.8 ± 7.2 3.0 ± 4.9 F = 23.33; P < 0.001
UCT scoreb 7.8 ± 4.3 7.2 (4.1) F = 5.86; P = 0.016
UCT scores < 12: n (%)b 2277 (77.5) 391 (82.8) Chi2 = 6.867; P = 0.009
CIndU chronic inducible urticaria; CSU chronic spontaneous urticaria; UCT urticaria control test
aBMI data was available for 3325 patients in the EU region and 243 patients in the C/SA region: the presented proportions are based on these denominators
bUCT data was available at visit 1 for 2939 patients in the EU region and 472 patients in the C/SA region: the presented proportions are based on these denominators
Fig. 1 Frequency of CIndU experience
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Patients in the C/SA region were also significantly less
likely to have been prescribed a therapy for CU within
the previous 12 months (which was discontinued prior
to the baseline visit) than patients in the EU region
(31.1% vs. 42.3%; P < 0.001).
CU patients in central and South America are less likely to
receive omalizumab treatment than patients in Europe
Among those receiving treatment, the recommended
first-line therapy for CU (i.e., sgH1-AH) were most com-
monly prescribed (77.4% EU vs. 86.1% C/SA; P = 0.001).
Escalation to third-line therapy with omalizumab had
occurred in significantly more EU patients than C/SA
patients (21.0% vs. 11.4%; P < 0.001), while escalation to
montelukast had occurred in significantly more C/SA
patients than EU patients (11.8% vs. 6.1%; P < 0.001).
Ciclosporin prescription was rare and comparable in
both populations, with current receipt by 1.2% of pa-
tients in the EU region and 1.4% of patients in the C/SA
region (P = 0.983). Current corticosteroid use was docu-
mented in 12.7% of patients receiving therapy in the EU
region vs. 8.6% in the C/SA region (P = 0.05). The use of
first generation H1-antihistamines was more prevalent
in the C/SA region (21.1% vs. 13.8%; P = 0.07). Among
those receiving a prior therapy, first generation
H1-antihistamines had been received by 21.2% of EU pa-
tients vs. 34.6% of C/SA patients (P < 0.001).
CU patients in central and South America show lower
quality of life impairment than patients in Europe
Patients in the EU region had significantly higher DLQI
scores than those in the C/SA region, indicating a greater
effect of CU on QoL (8.3 ± 7.0 vs. 6.5 ± 5.9; P < 0.001);
32.2% of patients in the EU region reported a very large or
extremely large effect of CU on QoL vs. 15.3% of patients
in the C/SA region; 22.2% vs. 16.3%, respectively, reported
a moderate impact (P < 0.001).
CU-driven work impairment is greater in patients in central
and South America
Among patients who were currently employed (57.5% in
the EU region and 56.1% in the C/SA region), the mean
(SD) estimated proportion of work time missed (i.e. ab-
senteeism), percentage impairment while working (i.e.
presenteeism) and the percentage overall work impair-
ment (i.e. work productivity loss) was significantly greater
for patients in the C/SA region compared to those in the
EU region (10.4 ± 19.7 vs. 6.7 ± 19.0, P = 0.004; 30.3 ± 31.9
vs. 24.4 ± 25.8, P = 0.001; and, 33.9 ± 33.9 vs. 26.5 ± 27.5,
P < 0.001, respectively). The estimated percentage of ac-
tivity impairment among H1-antihistamine-refractory
CU patients was also significantly greater for C/SA pa-
tients compared to EU patients (37.7 ± 34.7 vs. 32.7 ±
30.1, P = 0.001).
In both regions, patients with a primary diagnosis of
CU with angioedema had significantly greater impair-
ment in work and non-work activities compared to those
without angioedema (Table 3).
CU patients in central and South America show different
healthcare resource utilization than patients in Europe
Since CU diagnosis, a significantly greater proportion of
patients in the C/SA region had visited an emergency
room department due to urticaria than those in the EU
region (39.6% vs. 29.3%; P < 0.001). Additionally, patients
in the C/SA region had a higher frequency of visits to
emergency departments, 5.1 (15.1) vs. 3.5 (7.0), respect-
ively; (P = 0.005). However, hospitalizations due to urti-
caria were significantly more likely to occur among
patients from the EU region versus those from the C/SA
region (21.9% vs. 7.7%; P < 0.001) and patients in the EU
region were more frequent in the number of hospitaliza-
tions (2.0 [3.1] versus 0.3 [1.7], respectively; P < 0.001).
Similarly, visits to a general practitioner due to urti-
caria since diagnosis were significantly more common
among patients from the EU region versus those from
the C/SA region (57.3% vs. 31.7%; P < 0.001), with an
average of 7.8 (14.9) versus 1.7 (4.0) visits (P < 0.001), re-
spectively. In contrast, patients in the C/SA region were
significantly more likely to visit a dermatologist or
allergist versus those in the EU region (50.6% vs. 47.3%,
P < 0.001), but the average number of visits was non-
significantly greater in the EU region (7.5 [24.1] vs. 5.0
[14.9], P = 0.05). Other healthcare resources were used
due to urticaria since diagnosis by a significantly greater
proportion of patients in the EU region versus those in
the C/SA region (38.6% vs. 19.7%, P < 0.001).
In both the C/SA and EU regions, patients with a pri-
mary diagnosis of CSU with angioedema had a signifi-
cantly higher rate of healthcare resource utilization
compared to those without angioedema (Table 4). This
difference was particularly evident in terms of visits to
an emergency room and hospitalizations.
Discussion
This analysis of baseline data collected as part of the
AWARE study reveals that the clinical presentation of
H1-antihistamine refractory CU and its impact on QoL
and healthcare resource utilization is heterogeneous. Pa-
tients residing in the EU region compared with those in
the C/SA region are less likely to experience angioedema
and comorbid CSU and CIndU, have higher rates of con-
trolled disease and treatment (including higher rates of
escalation to omalizumab) and have lower rates of work
impairment. However, EU patients report a greater effect
of their condition on QoL than C/SA patients. Heterogen-
eity in healthcare resource use was also evidenced, with
EU patients more likely to visit a general practitioner and
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be hospitalized, and less likely to visit dermatologist or al-
lergists, or emergency departments.
A portion of the heterogeneity in disease severity may
be explained by the observed differences in both demo-
graphic characteristics and treatment. Patients in the C/
SA region were younger females who had been diag-
nosed for a shorter period of time. The observed higher
rates of uncontrolled disease and impact of disease upon
activity and work impairment may be linked to the lower
rates of treatment, particularly escalation to omalizumab.
Indeed, discrepancies in awareness of the current treat-
ment guidelines have been recently evidenced, with phy-
sicians in Ecuador (18%) exhibiting lower awareness
compared to physicians in Germany (33%) [17]. The
higher levels of QoL reported in the C/SA region are
not a new phenomenon: prior research has shown this
region to have inexplicably high QoL evaluations [29].
Within the present observational study conducted
across the EU and C/SA regions, the demographic char-
acteristics are comparable to those previously reported
within discrete countries: patients were predominantly
female, overweight, with a mean age of 42 years in the
EU region and 46 years in the C/SA region, and a pre-
ponderance of patients within the 18–40 age bracket
[30–32]. Interestingly, the present study found that pa-
tients in the C/SA region were more likely to be older
Table 3 DLQI and WPAI scores among patients with a primary diagnosis of CSU with or without angioedema
Region EU Region C/SA
PRO CSU with
angioedema
(n = 1721)
CSU without
angioedema
(n = 1760)
Significance
Test Statistic
CSU with
angioedema
(n = 250)
CSU without
angioedema
(n = 182)
Significance
Test Statistic
DLQI: mean (SD) 9.1 (7.5) 7.6 (6.3) F = 37.28; Ρ < 0.001 7.0 (6.4) 5.9 (5.5) F = 2.23; P = 0.137
No effect 17.8% 16.3% Chi2 = 65.413; Ρ < 0.001 24.7% 24.3% Chi2 = 4.4596; P = 0.347
Small effect 22.5% 29.5% 27.3% 33.1%
Moderate effect 20.7% 23.7% 21.3% 25.0%
Very large effect 28.0% 23.2% 22.0% 15.5%
Extremely large effect 9.5% 4.5% 4.7% 2.0%
WPAI Absenteeism:
mean (SD)
9.4 (22.6) 4.4 (14.8) F = 30.72; Ρ < 0.001 14.2 (23.6) 5.0 (12.7) F = 11.67; P = 0.001
WPAI Presenteeism:
mean (SD)
27.1 (27.5) 22.4 (24.2) F = 14.5; Ρ < 0.001 35.3 (33.2) 22.3 (28.9) F = 9.56; P = 0.002
WPAI Work Productivity
Loss: mean (SD)
29.6 (29.4) 24.2 (25.8) F = 16.82; Ρ < 0.001 39.9 (24.9) 24.3 (30.7) F = 11.63; P = 0.001
WPAI Activity Impairment:
mean (SD)
36.6 (31.9) 29.2 (28.1) F = 47.14; Ρ < 0.001 41.1 (36.2) 31.3 (31.3) F = 7.99; P = 0.005
Table 4 Healthcare resource use since diagnosis among patients with a primary diagnosis of CSU with or without angioedema
EU Region C/SA Region
Healthcare Resource CSU with
angioedema
(n = 1721)
CSU without
angioedema
(n = 1760)
Significance
Test Statistic
CSU with
angioedema
(n = 250)
CSU without
angioedema
(n = 182)
Significance
Test Statistic
Emergency room
Proportion of patients 40.4% 20.0% Chi2 = 175.474; Ρ < 0.001 54.0% 25.8% Chi2 = 38.379; P < 0.001
Frequency of visits 4.0 (8.1) 2.5 (4.1) F = 9.70; Ρ = 0.002 8.0 (19.0) 2.1 (8.9) F = 13.42; P < 0.001
Hospitalizations
Proportion of patients 29.1% 15.7% Chi2 = 90.023; Ρ < 0.001 11.4% 5.2% Chi2 = 4.913; P = 0.027
Frequency of visits 2.3 (3.7) 1.5 (1.2) F = 9.69; Ρ = 0.002 0.4 (2.1) 0.2 (1.3) F = 1.86; P = 0.173
General practitioner
Proportion of patients 61.9% 53.5% Chi2 = 24.977; Ρ < 0.001 38.1% 32.2% Chi2 = 1.547; P = 0.214
Frequency of visits 9.5 (18.4) 5.8 (9.0) F = 27.72; Ρ < 0.001 2.3 (5.0) 1.1 (2.5) F = 8.34; P = 0.004
Dermatologist or allergist
Proportion of patients 53.2% 41.2% Chi2 = 50.552; Ρ < 0.001 54.2% 54.0% Chi2 = 0.002;P = 0.966
Frequency of visits 7.9 (26.6) 7.0 (22.3) F = 0.41; P = 0.523 5.3 (11.3) 5.9 (20.6) F = 0.13; P = 0.715
Maurer et al. World Allergy Organization Journal             Page 6 of 10
females than those in the EU region. The frequency of
CSU and CIndU comorbidity has not yet been well doc-
umented; this study indicates that the comorbidity rate
in CSU patients who are refractory to H1-antihistamines
is approximately 20% among patients within the EU re-
gion and 28% around patients in the C/SA region. It is
critical in clinical practice to recognize the possibility of
such a co-occurrence, to ensure that patients are ad-
equately tested for potential urticaria triggers and allow
an individualized, personalized treatment approach. Al-
though there is no distinct treatment algorithm specific
to CIndU (that is, the guidelines recommend the same
treatment approach as that for CSU), it is known that
sgH1-AH do not reduce symptoms in all cases, and
while up-titrating the dose leads to further improvement
within these patients, it does not always lead to complete
symptom relief [33–35]. Studies and case reports suggest
that improvements similar to those observed with CSU
can be achieved with omalizumab [10, 11, 36, 37].
Previous studies have shown angioedema rates among
patients with CSU anywhere in the range from 33 to
85% [38–40]: in this multi-location study spanning Eur-
ope, Central America, and South America we identified
that 46% of EU region patients and 51% of C/SA region
patients experienced angioedema, with intensity ratings
that were predominantly of moderate or severe intensity.
It has been speculated that the varying rate of angio-
edema diagnosis among CU patients may be due to
variability in physician diagnoses and the lack of consist-
ently applied criteria [41]. Impairment in QoL, work,
and non-work activities were greater for patients with
angioedema compared to those without. This suggests
that it is critical to manage the angioedema associated
with CU, to reduce the patient burden. Additionally,
rates of healthcare resource utilization were found to be
much greater for patients with angioedema, particularly
in terms of emergency room visits and hospitalizations.
This supports the claim made by Staubach et al. [35]
that it is important to educate patients that angio-
edema in CSU patients is not life-threatening and can
be managed by dermatologists, allergists, or primary
care physicians.
The current urticaria guidelines recommend that
complete symptom control should be the aim of CU
treatment. Findings from this observational study sug-
gest that this goal is currently far from being achieved:
UCT scores evidenced that more than three quarters of
the recruited sample had uncontrolled urticaria despite
the average presence of symptoms for 5 years or more.
This issue was found to be significantly more prominent
in the C/SA region. According to the 2013 EAACI/
GA2LEN/EDF/WAO guidelines (relevant at the time of
the AWARE study), first-line treatment with sgH1-AH is
recommended, followed by an increase in dose (up to
4-fold) as second-line treatment and finally the addition
of omalizumab, ciclosporin, or montelukast to the
sgH1-AH as third-line treatment. [16] At the time of
baseline documentation, 31.9% of patients in the EU re-
gion and 43.1% of patients in the C/SA region were cur-
rently not receiving pharmacological treatment (ranging
from March 2014 for the earliest recruited patient to
April 2016 for the last recruited patient), despite being
diagnosed for a number of years, lack of urticaria con-
trol, a large effect of the condition of QoL, low treat-
ment satisfaction, and high healthcare resource
utilization. Moreover, the prescription of the recom-
mended third-line treatment to achieve complete symp-
tom control was present in less than 21% of the EU
population and less than 12% of the C/SA population,
and yet 76% and 83% of the populations, respectively, re-
ported uncontrolled urticaria. No data was collected on
the attribution for lack of treatment, because it was un-
anticipated during study design that treatment rates
would be so low. However, recent research suggests that
clinicians are not always following urticaria treatment
guidelines [17, 20, 42] and patients may have essentially
‘given up’ in favor of self-treatment or simply living with
the condition [41]. Another possible reason for non-
medication or non-escalation to third-line treatment
could be the differences in coverage and payment for
healthcare among EU and C/SA region. For example,
omalizumab is unavailable in some countries or its cost
is high and not covered by health insurance programs
(for example, in South America) [43]. In Ecuador, sys-
temic steroids and first generation antihistamines are
cheaper than sgAHs [17]. Economic considerations are
an important and decisive factor for the choice of
treatment.
Perhaps unsurprisingly, the rate of emergency health-
care resource use was high. However, it ought to be rec-
ognized that the AWARE study does not allow for an
assessment of current healthcare resource use in general.
This is particularly pertinent considering the findings
from the cross-sectional web-based survey of patients
diagnosed with CU in Germany, which revealed that
only 40% of symptomatic patients were under physician
care: the majority had stopped consulting a physician
[41]. Similar results have been reported in Italy [42].
Thus, the burden of CU may be greater than currently
estimated, if a substantial proportion of patients have
stopped consulting healthcare professionals despite con-
tinuation of symptoms. The low rates of treatment satis-
faction and high rates of uncontrolled urticaria found
within the present study may be associated with this
issue and further investigation is warranted.
Interestingly, within the EU region patients were con-
sulting primary care physicians for their urticaria at a
higher rate than that for dermatologists and allergists.
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This finding is novel: previous studies have reported that
patients primarily consult with dermatologists or aller-
gists about their condition [30, 42]. Thus, it is important
to recognize that primary care physicians are a crucial
part of the treatment team within the EU region and en-
suring physicians are educated in line with the guideline
recommendations is necessary.
Overall, across both the EU and C/SA regions, chronic
urticaria is largely uncontrolled, under treated, is associ-
ated with a high healthcare resource use burden, and
has a large effect on quality of life, work, and activity.
Among patients who are treated, escalation to third-line
therapies as recommended within the treatment guide-
lines is rare, despite the lack of disease control, low rates
of patient satisfaction with treatment, and frequency of
healthcare resource use. Further, this study identified
that patients residing within the C/SA region versus the
EU region have a greater uncontrolled symptom burden,
a greater effect of CU on work, productivity, and activ-
ity, and a lower overall treatment rate. Additionally, pa-
tients within the C/SA region have a greater incidence
of urticaria induced in response to a specific stimuli than
patients in the EU region, with the latter more likely to
experience spontaneous urticaria. This study also re-
vealed that CU within the C/SA region is associated with
a significantly greater incidence of emergency room
visits and a significantly lower incidence of general prac-
titioner visits. This suggests a potential benefit from
greater education efforts at both the physician and pa-
tient level within the C/SA region. The differences iden-
tified between EU and C/SA region although statistically
significant and relevant on a population level, do not
prove that these regional differences are clinically signifi-
cant for patients as individuals. An investigation of the
individual clinical significance of the differences identi-
fied in this study requires longitudinal data, which
should be the focus of further investigations. Potential
reasons for the differences between regions include dif-
ferences in how physicians approach CSU, e.g. differ-
ences in awareness of the need for symptomatic
treatment that results in control of CSU and the absence
of signs and symptoms, differences in the availability of
treatment options, as well as differences in economic re-
sources and funding for these options. It is likely that, in
addition, differences in how patients approach CSU are
related to the differences identified, e.g. differences in
how satisfied patients are with partial response, differ-
ences in the availability of treatment and whether pa-
tients can afford to pay for it, as well as cultural
differences in the perception of the burden of disease.
Our results should encourage physicians, independent of
the regions they work in, to aim for a reduction of
non-treatment and under-treatment in their patient pop-
ulations. The objectives of management, together with
the means available to achieve these objectives, should
be clearly discussed with patients, i.e., controlled disease
and absence of signs and symptoms.
Strengths of the present study include the inclusion of
patients across Europe, South America, and Central
America, which allows for a multi-national understand-
ing of the current urticaria situation. New insight is pro-
vided in to the disease burden at both the personal and
societal level and current adherence to treatment guide-
lines. The study is limited due to the dependence on
physicians and patients for data completeness and
quality as well as the physicians’ free choice to enrol
patients with CU refractory to regular doses of
H1-antihistamines, independently of disease severity
or medication needed to control symptoms and signs.
Efforts were made at each site to encourage physi-
cians to ensure that data records were filled in com-
pletely and accurately.
Conclusions
This initial baseline analysis of the AWARE study re-
veals a high unmet need of H1-antihistamine refractory
CU patients. Critically, this study revealed that CU is a
heterogeneous condition with differences in healthcare
utilization and outcomes between Europe and Central
and South America. Further research is warranted to in-
vestigate the condition globally and identify region-
specific features that may be used to inform public
health strategies. There is a need for improved patient
care, physician education, and adherence to current
treatment guidelines, alongside harmonization of the
management of CU globally, such that patients are re-
ceiving the highest standard care available based on the
most current knowledge. The development of a world-
wide network of urticarial centers of reference and ex-
cellence, alongside a global urticarial registry, may help
to achieve this.
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